I think we should have a separate thread to unpack Roger's latest interview.
I think he was quite reluctant to make any bold statements, but he did provide a nod and a wink to the ultimate ambition which is success of MPL as a Human Cancer therapeutic. All along, that has been PAA's major goal, and if we can achieve our niche in the Human Cancer market, then shareholders will be reaping out-sized benefits.
My overall impression is that he was doing a balancing act - providing basic information to new investors while also attempting to bolster and re-assure existing shareholders.
Clinical Trials Interview June 2022
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $77.79M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $244.5K | 1.554M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 306564 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 46887 | 3 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |